Multitude Therapeutics Inc.
Clinical trials sponsored by Multitude Therapeutics Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug AMT-676 enters first human tests Results expected May 2027 (estimated)
- New drug duo takes on advanced lung cancer Results expected May 2027 (estimated)
-
New hope for advanced colon cancer: experimental combo enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug called AMT-676 combined with standard chemotherapy and targeted therapy for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow the disease. About 180 a…
Phase 2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug duo takes on advanced lung cancer
Disease control Recruiting nowThis study tests a new combination of two drugs, AMT116 and ivosimab, in people with advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18 to 75 will take part…
Phase 1/2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cancer drug AMT-676 enters first human tests
Disease control Recruiting nowThis early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…
Early phase 1 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug AMT-253 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the dr…
Phase 1/2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:59 UTC